MedTrace Logo

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

NCT00901147 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-06-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether intravenous Bortezomib combined with oral Panobinostat (LBH589) are effective in treating adult patients with relapsed/refractory peripheral T-cell lymphoma or NK/T-cell lymphoma after the failure of conventional chemotherapy.

Conditions

  • Peripheral T-cell Lymphoma (Not Otherwise Specified)
  • Angioimmunoblastic T-cell Lymphoma
  • Extranodal NK/T-cell Lymphoma Nasal Type
  • Enteropathy- Type T-cell Lymphoma
  • Hepatosplenic T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
  • Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant

Interventions

DRUG

panobinostat and bortezomib

oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle

Sponsors & Collaborators

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Yeow Tee Goh, MBBS MMed · Singapore General Hospital

  • Darryl Tan, MBBS MMED · Singapore General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Malaysia
  • Singapore
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901147 on ClinicalTrials.gov